Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

CheckMate 9ER: Nivolumab Plus Cabozantinib in Newly Diagnosed Advanced RCC

March 15th 2024

The expert panel reacts to 55-month follow-up data from CheckMate 9ER assessing nivolumab plus cabozantinib in patients with newly diagnosed advanced RCC.

Retrospective Study Shows Neoadjuvant SCRT is Associated With Optimal Surgical Outcomes in Rectal Cancer

March 14th 2024

Prolonged duration from neoadjuvant SCRT to surgery did not increase the risk of poor mesorectum specimen quality or post-operative morbidity in rectal cancer.

Dr Rini on the FDA Approval of Belzutifan in Relapsed/Refractory RCC

March 13th 2024

Brian I. Rini, MD, FASCO, shares the importance of the FDA approval of belzutifan in patients with advanced renal cell carcinoma.

Clinical Insights on Recent Data in Metastatic Urothelial Carcinoma

March 11th 2024

GU medical oncologists offer their impressions of recent updates in the metastatic urothelial carcinoma space, focusing on CheckMate 901 and EV-302.

Emerging Data in Metastatic Urothelial Carcinoma

March 11th 2024

Neeraj Agarwal, MD, FASCO, provides a comprehensive overview of recent data in metastatic urothelial carcinoma, highlighting the CheckMate 901 and EV-302 studies.

Dr Xu on Treatment Sequencing Considerations in Metastatic Renal Cell Carcinoma

March 10th 2024

Wenxin (Vincent) Xu, MD, discusses the factors he takes into account when sequencing treatment options for patients with metastatic renal cell carcinoma.

Dr Tagawa on the Role of PARP Inhibitors in Prostate Cancer Treatment

March 9th 2024

Scott T. Tagawa, MD, MS, FACP, FASCO, discusses the standing of PARP inhibitors in the treatment paradigm of metastatic castration-resistant prostate cancer.

Dr Dreicer on Improving Clinical Trial Design in Prostate Cancer

March 9th 2024

Robert Dreicer, MD, discusses the shortcomings of current clinical trials in prostate cancer and what he sees as the biggest area of improvement.

Lenvatinib Plus Pembrolizumab Network Meta-Analysis and Outcomes with Cabozantinib in Advanced RCC

March 8th 2024

David A. Braun, MD, PhD, shares his takeaways from the network meta-analysis on lenvatinib plus pembrolizumab in advanced RCC, and Martin H. Voss, MD, discusses outcomes with cabozantinib following frontline lenvatinib plus pembrolizumab.

LEAP Study: Lenvatinib Plus Pembrolizumab in Patients With RCC and Brain Metastasis

March 8th 2024

Chandler H. Park, MD, discusses the LEAP study investigating lenvatinib plus pembrolizumab in patients with renal cell carcinoma with brain metastasis.

Dr Gopal on the Nuances of IO/TKI Selection in Advanced RCC

March 7th 2024

Nikhil A. Gopal, MD, discusses the nuances of treatment decision-making in advanced renal cell carcinoma.

Dr Gopal on the Evolution of TKI/IO Combination Approaches in RCC

March 7th 2024

Nikhil A. Gopal, MD, discusses the transition of treatment with TKIs to treatment with TKI/IO combinations for those with renal cell carcinoma.

Expert Insights on Updates in Adjuvant Therapy for Muscle-Invasive Bladder Cancer

March 4th 2024

Experts on muscle-invasive bladder cancer respond to recent data in adjuvant therapy that were presented at ASCO GU 2024.

Recent Updates in Adjuvant Therapy for Muscle-Invasive Bladder Cancer

March 4th 2024

Following an overview of the evolving adjuvant therapy space, Matthew Milowsky, MD, FASCO, reviews recent updates from ASCO GU 2024 in muscle-invasive bladder cancer.

Neoadjuvant Tislelizumab Plus Axitinib Generates Responses in Locally Advanced ccRCC

March 2nd 2024

Neoadjuvant tislelizumab plus axitinib demonstrated clinical efficacy and safety in patients with nonmetastatic clear cell renal cell carcinoma.

Recent Subgroup Analyses from the CLEAR study in Advanced RCC

March 1st 2024

Martin H. Voss, MD, gives an overview of the CLEAR study evaluating lenvatinib plus pembrolizumab in frontline advanced RCC and discusses recent subgroup analyses.

CheckMate 67T: Subcutaneous vs IV Nivolumab in Previously Treated Advanced RCC

March 1st 2024

Laurence Albigès, MD, PhD, reviews recently presented data from CheckMate 67T, which is assessing subcutaneous vs intravenous nivolumab in patients with previously treated RCC.

Dr Rini on the Utility of Belzutifan in RCC

March 1st 2024

Brian I. Rini, MD, FASCO, discusses the background that led to the FDA approval of belzutifan for patients with advanced renal cell carcinoma.

Belzutifan Regimens Show Promise in RCC as Frontline IO/TKI Armamentarium Expands

February 28th 2024

Nikhil A. Gopal, MD, discusses the benefit of belzutifan in addition to effective immunotherapy-based regimens in advanced RCC.

Dr Gopal on the Advantages and Potential Benefit of Belzutifan in RCC

February 27th 2024

Nikhil A. Gopal, MD, discusses the benefit of belzutifan for patients with renal cell carcinoma.